Welcome to our dedicated page for Lixte Biotechnology Hldgs SEC filings (Ticker: LIXT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lixte Biotechnology Holdings, Inc. filings document a clinical-stage oncology issuer developing cancer treatments through LB-100, Liora Technologies Europe and related platform assets. Annual and periodic disclosure categories cover operating and financial results, clinical and regulatory matters, capital structure, governance and the company's single reportable development segment.
Material-event filings record definitive agreements, subsidiary-level consulting and allocation arrangements, compensation changes, stock option cancellations, restricted share unit awards under the 2020 Stock Incentive Plan, and other capital-structure matters. Proxy materials cover shareholder voting, board governance and executive-compensation disclosures.
Lixte Biotechnology Holdings (LIXT) completed a share exchange to acquire all shares of Liora Technologies Europe Ltd., which owns the LIGHT proton-based radiotherapy assets previously acquired from Advanced Oncotherapy. As consideration, Lixte will issue 2,700 shares of Series C Preferred Stock, convertible into 2,700,000 common shares (subject to a 19.99% cap until shareholder approval), pay 10.56 Bitcoin, 300 Ethereum, and $440,000 in cash, and enter a royalty agreement. The royalty entitles the seller to 10% of Net Revenue from the LIGHT equipment, up to a $45,000,000 cap, with quarterly calculations and audit rights. The new Series C Preferred Stock is non‑voting, non‑dividend bearing, convertible at a 1,000:1 ratio into common stock, and carries ownership limits tied to Nasdaq shareholder approval requirements.
Lixte Biotechnology Holdings (LIXT) filed its Q3 2025 10‑Q, reporting a net loss of $1,980,398 for the quarter and $3,465,626 for the nine months. The quarter reflected $50,696 in research and development and $1,750,658 in general and administrative costs, with a basic and diluted net loss per share of $0.33.
As of September 30, 2025, cash was $2,887,874. The company held digital assets (Bitcoin and Ethereum) of $2,454,473 at fair value and recorded an unrealized loss of $182,887. Lixte completed equity financings in July 2025, including a $5.05 million private placement and a $1.5 million registered direct offering, and subsequently regained Nasdaq stockholders’ equity compliance on July 15, 2025.
Management disclosed substantial doubt about the company’s ability to continue as a going concern, while estimating existing cash supports operations for at least 12 months from quarter-end. Shares outstanding were 5,704,200 as of November 5, 2025.
Lixte Biotechnology Holdings, Inc. called its 2025 Annual Meeting to vote on three items: elect five directors, ratify Weinberg & Company, P.A. as auditor, and amend the 2020 Stock Incentive Plan to increase shares issuable by 2,750,000 to a total of 3,500,000 shares.
The virtual meeting is on December 8, 2025 at 1:00 p.m. ET. The record date is October 14, 2025, when 5,704,200 common shares were outstanding and entitled to vote. Director nominees are Geordan Pursglove, Jason Sawyer, Dr. Michael Holloway, Lourdes Felix and Guy Primus. The board recommends voting “FOR” all proposals.
As context, under the 2020 Plan, unexpired stock options for 694,309 shares were outstanding and 55,691 shares remained available as of September 30, 2025. The company reports a three‑year average net burn rate of 6.1%. For audit services, fees billed to Weinberg totaled $143,618 in 2024.